You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Impact of Gut Permeability on Estimation of Oral Bioavailability for Chemicals in Commerce and the Environment
Abstract
Administered equivalent dose (AED) estimation using in vitro hazard and high
throughput toxicokinetics (HTTK) can be improved by refining assumptions
regarding fraction absorbed ($F_{abs}$) through the intestine, a component of
oral bioavailability ($F_{bio}$). Although in vivo data to inform $F_{abs}$
are often unavailable for non-pharmaceuticals, in vitro measures of apparent
permeability ($P_{app}$) using the Caco-2 cell line have been highly correlated
with $F_{abs}$ when used in in vitro-in vivo extrapolation (IVIVE) modeling.
To address data gaps for non-drug chemicals, bidirectional $P_{app}$ was
evaluated using the Caco-2 assay for over 400 chemicals. A random forest
quantitative structure-property relationship (QSPR) model was developed using
these and peer-reviewed pharmaceutical data. Both Caco-2 data ($R^2$=0.37) and
the QSPR model ($R^2$=0.3) were better at predicting human bioavailability
compared to in vivo rat data ($R^2$=0.2). The httk-predicted plasma steady
state concentrations ($C_{ss}$) for IVIVE were updated, leading to modest
changes for poorly absorbed chemicals. Experimental data were evaluated for
sources of measurement uncertainty, which was then accounted for using the Monte
Carlo method. Revised AEDs were subsequently compared with exposure estimates to
evaluate influence on bioactivity:exposure ratios as a surrogate for risk.
Ultimately, $P_{app}$ incorporation to adjust for $F_{bio}$ in httk modeling
improves AED estimations used in HT risk prioritization.
U.S. Environmental Protection Agency, Office of Research and Development, Center for Computational Toxicology and Exposure, Research Triangle Park, NC 27711, USA